Emmanuelle Toussaint Named Executive Director of BIOQuébec
Emmanuelle Toussaint Named Executive Director of BIOQuébec

BROMONT, Quebec--(BUSINESS WIRE)--BIOQuébec’s Board of Directors is proud to announce the appointment of Emmanuelle Toussaint as Executive Director, effective immediately. “We are very pleased to have Emmanuelle join us as Executive Director. She is tremendously influential in the business community, and her diverse professional experiences, paired with her leadership, energy, and passion, will be greatly appreciated by BIOQuébec and our partners,” indicated Frédéric Leduc, President of the Board. “BIOQuébec has been supporting its members for over thirty years, and I firmly believe that Emmanuelle will take BIOQuébec to new heights.”

Read More
press releaseGuest UserBIOOQuébecBIOQuébec, Executive director, Appointment
Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology
Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology

Strasbourg, France – Montreal, Canada, June 28, 2022 – Domain Therapeutics, a biopharmaceutical company focusing on the research and development of innovative drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announced that it obtained a single digit multimillion milestone payment from Merck as part of the €240m ($261m) milestone payments and undisclosed royalties collaboration and license partnership signed in 2017.

Read More
NewsGuest Userresearch, immuno-oncology, M1069, clinical development stage
ExCellThera announces submission of Drug Master File for UM171
ExCellThera announces submission of Drug Master File for UM171

MONTRÉAL, June 17, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for UM171, a proprietary molecule being studied for use in the expansion and rejuvenation of hematopoietic stem cells.

Read More
NewsGuest UserExCellThera, FDA, DMF, clinical-stage, biotechnology
Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101
Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

LAVAL, Québec, June 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that three composition of matter patents for GTX-104 were issued by The United States Patent and Trademark Office, the Japanese Patent Office, and the Australian Patent Office. Additionally, one new patent for GTX-104 was awarded by the Indian Patent Office. These granted patents are all valid until 2037.

Read More
NewsGuest UserBIOOQuébecGTX-104, GTX-101, Acasti Pharma
Launches of new medicines in Canada declined consistently in recent years: new data
Launches of new medicines in Canada declined consistently in recent years: new data

TORONTO, Ontario – June 13, 2022 – The launches of new medicines in Canada declined consistently and markedly in Canada over the past five years as ongoing changes to the pharmaceutical policy environment, including federal medicine pricing reforms (i.e., PMPRB reforms), have caused uncertainty about the Canadian market.

Read More
press releaseGuest UserBIOOQuébecNew medicines launches, Canada, IQVIA
Partnering with owners and management, ArchiMed and the CDPQ invest in Corealis Pharma
Partnering with owners and management, ArchiMed and the CDPQ invest in Corealis Pharma

The significant recapitalization of the Americas' leading CDMO for pharmaceutical oral solid dosage formulation and clinical supply manufacturing will accelerate growth, including the build-out of State-of-the-Art Laboratories and Good Manufacturing Practices-compliant facilities.

LYON, France and MONTRÉAL and LAVAL, QC, May 31, 2022 /CNW Telbec/ - Trans-Atlantic private equity healthcare specialist ArchiMed and global investor group Caisse de dépôt et placement du Québec (CDPQ) have invested in Corealis Pharma. The partnership will further expand the high-quality drug development services Corealis offers as a Contract Development and Manufacturing Organization to small and medium-sized biotech and pharma companies.

Founded in 2005 and based in Laval, Québec, Canada, Corealis is the market-leading CDMO in the Americas for the formulation development and manufacture of oral solid dosage pharmaceuticals – tablets, capsules, and granules – during pre-commercialization preclinical and clinical phases.

Read More
NewsGuest UserArchiMed, Corealis, clinical supply manufacturing
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

Jun 1, 2022

Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential development, regulatory, commercial and sales milestones, plus royalties on global net product sales

Repare to host conference call today at 5:00 p.m. EDT

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Jun. 1, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500), a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of tumors with specific synthetic-lethal genomic alterations including those in the ATM gene (Ataxia-Telangiectasia mutated kinase). Under the collaboration, Roche will assume development of camonsertib with the potential to expand development into additional tumors and multiple combination studies.

Read More
NewsGuest UserRepare Therapeutics, RP-3500
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

LAVAL, Québec, May 18, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage (SAH), met all its planned study endpoints. The primary objective of the study was to evaluate the relative bioavailability of IV GTX-104 compared to oral nimodipine in healthy adult male and female subjects, while the secondary objective was to assess its safety and tolerability. The Company plans to submit these results to the US Food and Drug Administration (FDA), along with its proposed study design for the Phase 3 safety study which is on track to start in the second half of 2022. The safety study is expected to be the final step required to seek regulatory approval under the 505(b)(2) regulatory pathway before submitting a New Drug Application to the FDA.

Read More
NewsGuest UserBIOOQuébecstudy report, FDA, quebec, innovation
A Framework for Action to Support Quebec’s Biopharmaceutical Innovations and Bolster Quebec’s Autonomy
A Framework for Action to Support Quebec’s Biopharmaceutical Innovations and Bolster Quebec’s Autonomy

BIOQuébec commissioned The JBL Group to produce a comprehensive account of the situation by first, rigorously documenting the Quebec healthcare system’s recommendation process for Quebec-based innovations and secondly, to develop, with industry partners, public policy proposals that would support the Quebec biopharmaceutical industry’s innovations and development. BIOQuébec’s review was prompted by a widespread perception among many members that Quebec-based drugs and biopharmaceutical industry products were unfavourably considered by the Quebec health and social services network.

Read More
studyreportGuest UserBIOOQuébecinnovation, study report, biopharmaceutical
The PMPRB Will Not Move Forward with Changes to the Patented Medicines Regulations
The PMPRB Will Not Move Forward with Changes to the Patented Medicines Regulations

On April 14, 2022, the Minister of Health announced that the federal government would not implement the changes to the patented medicines regulations introducing new pharmaco-economic factors and requiring that information related to cost and revenues be disclosed. The federal government will move forward with the changes which use a new basket of comparative countries. These amendments are expected to come into force on July 1, 2022.

Read More
NewsGuest Userpharmaco-economic, medicines regulations, decision, minister of health
Quebec’s Life Sciences Strategy 2022-2025: A Promising Plan for BIOQuébec’s Members and Quebec’s Life Sciences Industry
Quebec’s Life Sciences Strategy 2022-2025: A Promising Plan for BIOQuébec’s Members and Quebec’s Life Sciences Industry

BROMONT, Québec--(BUSINESS WIRE)--BIOQuébec welcomes the tabling of the 2022-2025 Quebec Life Sciences Strategy (QLSS) which will support - and above all, foster - the growth of Quebec’s life sciences ecosystem. The second version of the QLSS features three major objectives, five areas of focus, and ten promising measures for the industry.

Read More
press releaseGuest Userinvestment, biotechnology, Strategy
CQDM funds an innovative project with Altus Formulation and Tetra Bio-Pharma to develop first-in-class treatments for ocular inflammation
CQDM funds an innovative project with Altus Formulation and Tetra Bio-Pharma to develop first-in-class treatments for ocular inflammation

During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection of lung cancer. Funding for this collaborative research project is made possible with the financial support of the ministère de l’Économie et de l’Innovation (MEI) who will be providing $1.36M as part of CQDM’s SynergiQC program.

Read More
NewsGuest UserCQDM, AltusFormulation, Funding, ocular, blindness